Artículos Científicos en Ingles

Artículos Científicos RSS AJKD

G-476 Minimal Change Disease and Thymoma: A 14-Year Struggle and the Role of Steroid-Sparing Agents

Este artículo no posee resumen

G-477 Living with IgA Nephropathy: A Focus Group Study on the Patient Experience

Este artículo no posee resumen

G-478 DNAJB9 Fibrillary Glomerulonephritis in a Patient with SLE

Este artículo no posee resumen

G-479 A Mechanistic Biopsy Study to Evaluate Structural and Functional Changes in Kidneys of Patients with IgA Nephropathy (IgAN) Receiving Iptacopan on Top of Supportive Care

Este artículo no posee resumen

G-480 Lupus Vasculopathy: A Call to Action for Enhanced Awareness and Research

Este artículo no posee resumen

G-481 Exploring the Risk of Thrombotic Microangiopathy (TMA) in Anti-VEGF Therapy: A Global Multicentric Retrospective Analysis

Este artículo no posee resumen

G-482 Membranous Nephropathy as an extraintestinal manifestation of Ulcerative colitis

Este artículo no posee resumen

G-465 Approach to Treat Glomerulopathy Without Electron Microscopy Findings

Este artículo no posee resumen

G-464 Baseline Demographics, Clinical Characteristics, and Medical History of an Initial Cohort of Patients Receiving Voclosporin for Lupus Nephritis in the Enlight-LN Registry

Este artículo no posee resumen

G-447 AFFINITY Study: 1Y Results of Atrasentan in IgAN in Patients with UPCR <1 and ≥1g/g

Este artículo no posee resumen

G-448 Immunotactoid Glomerulopathy as a presentation of untreated Chronic Lymphocytic Leukemia (CLL)

Este artículo no posee resumen

G-449 Primary Membranous Nephropathy in a Kidney Donor After COVID-19 Infection

Este artículo no posee resumen

G-450 Pegcetacoplan for Post-Transplant Recurrent C3 Glomerulopathy or Idiopathic Immune Complex-Mediated Gomerulonephritis: The VALIANT Trial

Este artículo no posee resumen

G-451 An Unusual Case of Malignant Transformation: From Type II Cryoglobulinemia MGRS to Lymphocytoplasmacytic Lymphoma

Este artículo no posee resumen

G-452 Sparsentan (SPAR) as First-Line Treatment of Incident Patients With IgA Nephropathy (IgAN): Interim Analysis of the SPARTAN Trial

Este artículo no posee resumen

Páginas